Moreover, Cavelti-Weder et al. studied the safety and efficacy of gevokizumab, a human monoclonal anti-IL1β antibody, on T2DM patients in a placebo-controlled setting [92]. Here, IL1B is linked to type 2 diabetes mellitus.